CureDuchenne and Avidity Biosciences: EXPLORE44TM

Join Cure Duchenne’s webinar as we welcome Kelly DiTrapani and Mark Stahl from Avidity Biosciences for a presentation and discussion on the EXPLORE44TM clinical trial. EXPLORE44 is a Phase 1/2 clinical trial evaluating AOC 1044 for the treatment of individuals with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44). AOC 1044 is an antibody oligonucleotide conjugate (AOCTM) and is designed to use an antibody to deliver an exon 44-skipping oligonucleotide to muscle and heart cells. AOC 1044 is the first of multiple AOCs Avidity is developing for the Duchenne community.